Skip to main content
APMD
NASDAQ Life Sciences

Apnimed Posts $29.5M Q3 Loss; $351.8M Cash Funds Launch Into Q2 2028

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Healthcare
Sentiment info
Neutral
Importance info
7
Price
$16.92
Mkt Cap
$704.393M
52W Low
$13.88
52W High
$35.29
52W Position info
22% above low
Off High info
52% below high
Rel. Volume info
1.5× avg
Market data snapshot near publication time

APMD sits 22% above its 52-week low of $13.88.

Summary

Apnimed reported a $29.5M Q3 2026 net loss as launch preparation drove G&A up sharply, but $351.8M in cash funds operations into Q2 2028 — beyond the February 28, 2027 FDA decision date for Oxnimbi.


Key Events · Earnings and Guidance · APMD

  • Q3 Net Loss Widens to $29.5M

    Net loss was $29.5M for the quarter ended September 30, 2026, versus $10.9M a year earlier, driven by launch-related spending.

  • G&A Jumps on Launch Preparation

    General and administrative expenses rose to $22.6M from $6.0M, including $4.0M of launch infrastructure and $4.4M of stock-based compensation; R&D rose 20% to $11.8M.

  • Cash Runway Past FDA Decision

    $351.8M in cash and equivalents at September 30, 2026 is expected to fund the potential U.S. launch of Oxnimbi and operations into the second quarter of 2028.

  • Oxnimbi PDUFA Set for February 28, 2027

    The NDA for AD109 (proposed name Oxnimbi) remains under FDA review with a PDUFA goal date of February 28, 2027; commercial readiness activities are advancing.


Analysis · APMD · Life Sciences

Apnimed's first quarterly report as a public company shows the cost of preparing to launch Oxnimbi: G&A jumped to $22.6M from $6.0M a year ago, pushing the net loss to $29.5M from $10.9M. The offset is a $351.8M cash pile from the August IPO that management says funds operations into Q2 2028 — past the February 28, 2027 PDUFA date, so the company does not need to raise money before an FDA decision. That removes near-term financing risk from the story; the binary event is now the FDA's ruling on AD109.

How filings like this one have moved

In the 30 days to Nov 15, 2026, 37.5% of the 3713 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, APMD was trading at $16.92 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $704.4M. The 52-week trading range was $13.88 to $35.29. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

APMD - Latest Insights

APMD
Nov 13, 2026, 4:45 PM EST
Filing Type: 8-K
Importance Score:
8
Price at Filing: $16.92
Real-time Price: $16.92 info
Change: $0 (0%) info
Market Cap: $704.393M info
APMD
Sep 08, 2026, 5:12 PM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $28.79
Real-time Price: $16.92 info
Change: -$11.87 (-41%) info
Market Cap: $704.393M info
APMD
Sep 08, 2026, 5:10 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $28.79
Real-time Price: $16.92 info
Change: -$11.87 (-41%) info
Market Cap: $704.393M info
APMD
Sep 08, 2026, 4:39 PM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $28.79
Real-time Price: $16.92 info
Change: -$11.87 (-41%) info
Market Cap: $704.393M info
APMD
Aug 03, 2026, 4:35 PM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $25.00
Real-time Price: $16.92 info
Change: -$8.08 (-32%) info
Market Cap: $704.393M info